Journal article icon

Journal article

Valvular heart disease and the use of cabergoline for the treatment of prolactinoma.

Abstract:

OBJECTIVE: The use of high doses of the ergot-derived dopamine agonist cabergoline (> 3 mg/day), especially with cumulative doses > 4000 mg, has been associated with an increase in cardiac valvular thickening and significant (moderate to severe) regurgitation. Whether lower doses commonly used in the treatment of prolactinomas (0.25-3 mg/week) are also associated with significant valvulopathy is controversial. The mitral valve tenting area, a subclinical index of leaflet stiffening, ha...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD
Szmigielski, C More by this author
More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, RDM, OCDEM
Journal:
Clinical endocrinology
Volume:
70
Issue:
1
Pages:
104-108
Publication date:
2009-01-05
DOI:
EISSN:
1365-2265
ISSN:
0300-0664
URN:
uuid:3552508c-04c7-40e9-94f1-35dc5dca15ae
Source identifiers:
26217
Local pid:
pubs:26217

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP